Figure 7
From: Role of Vitamins A and D in BCR-ABL Arf−/− Acute Lymphoblastic Leukemia
Effect of retinoids and RAR- and RXR-specific agonists on the number of viable BCR-ABL Arf−/− ALL cells. Effect of 48 hr ATRA or vehicle (control) treatment of BCR-ABL ALL cells in suspension culture on (A) BCR-ABL ALL viable cell number, n = 3 per group (B) Percentage of apoptotic (Annexin V positive) cells, n = 3 per group; and (C) Percentage of cells in each phase of the cell cycle, n = 3 per group. (D–E) The number of viable BCR-ABL leukemia cells measured by MTT or MTS assay following 48 hr treatment with various doses of (A) ATRA or RARα, β, γ specific agonists, (E) RARβ vs. RXRα specific agonist, or (F) ATRA, 9-cis-retinoic acid (9-Cis RA), bexarotene (BEX), or RARγ specific agonist, n = 4 per group. The unpaired t-test with Welch’s correction was used to determine significance between the treatments in Fig. 7A,B,D–F as appropriate (**p < 0.01 *p < 0.05).
